trial

Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia

NCTId NCT07075237
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Not Yet Recruiting
Enrollment 120 (estimated)
Sponsored by Jiangsu Province Nanjing Brain Hospital
Primary completion 2026-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Not Yet Recruiting
Enrollment
120 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2025-10
Primary completion
2026-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Paliperidone

Sponsors

Jiangsu Province Nanjing Brain HospitalLead Sponsor

Sites

1 total
Nanjing, China

Facts & assertions

4 sourced
Enrollment
120
Phase
PHASE4
Primary Completion Date
2026-10
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
Paliperidone
drug
lead_sponsor
Jiangsu Province Nanjing Brain Hospital
company
indication
Schizophrenia
indication
Schizophrenia
indication
Social Adjustment
indication